Emerging strategies for the clinical application of rapamycin

Clinical Biochemistry

Volumn 31, Issue 5, 1998, Pages 341-344

  Kahan, Barry D ^a  

^a UNIVERSITY OF TEXAS MEDICAL SCHOOL   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

AZATHIOPRINE; CORTICOSTEROID; CYCLOPHILIN; CYCLOSPORIN A; CYTOCHROME P450; FK 506 BINDING PROTEIN; IMMUNOPHILIN; INTERLEUKIN 2 RECEPTOR; LYMPHOCYTE ANTIBODY; MONOCLONAL ANTIBODY CD3; PROTEIN KINASE; PROTEIN P27; RAPAMYCIN;

BONE MARROW DEPRESSION; CELL CYCLE; CLINICAL TRIAL; CONFERENCE PAPER; DRUG MECHANISM; DRUG POTENCY; GRAFT REJECTION; HUMAN; IMMUNOPROPHYLAXIS; IMMUNOSUPPRESSIVE TREATMENT; KIDNEY TRANSPLANTATION; NEPHROTOXICITY; NONHUMAN; PRIORITY JOURNAL; SIGNAL TRANSDUCTION;

ANIMALS; CYCLOSPORINE; DRUG THERAPY, COMBINATION; GRAFT REJECTION; HUMANS; IMMUNOSUPPRESSIVE AGENTS; SIROLIMUS; TRANSPLANTATION IMMUNOLOGY;

EID: 0032128396     PISSN: 00099120     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0009-9120(98)00044-7     Document Type: Conference Paper

References (22)

1. Sehgal S.N., Baker H., Vezina C. Rapamycin (AY-22, 989), a new antifungal antibiotic. II. Fermentation, isolation and characterization. J Antibiot (Tokyo). 28:1975;727-732.
2. Brown E.J., Beal P.A., Keith C.T., Chen J., Shin T.B., Schreiber S.L. Control of p70 S6 kinase activity of FRAP in vivo. Nature. 377:1995;441-446.
3. Albers M.W., Williams R.T., Brown E.J., Tanaka A., Hall F.L., Schreiber S.L. FKBP-rapamycin inhibits a cyclin-dependent kinase activity and a cyclin D1-Cdk association in early G1 of an osteosarcoma cell line. J Biol Chem. 268:1993;22825-22829.
4. Andoh T.F., Lindsley J., Franceschini N., Bennett W.M. Synergistic effects of cyclosporine and rapamycin in a chronic nephrotoxicity model. Transplantation. 62:1996;311-316.
5. Kahan B.D. Cyclosporine. N Engl J Med. 321:1989;1725-1738.
6. Andoh T.F., Burdmann E.A., Fransechini N., Houghton D.C., Bennett W.M. Comparison of acute rapamycin nephrotoxicity with cyclosporine and FK506. Kidney Int. 50:1996;1110-1117.
7. Stepkowski S.M., Napoli K.L., Wang M.E., Qu X., Chou T.C., Kahan B.D. Effects of pharmacokinetic interaction between orally administered sirolimus and cyclosporine on the synergistic prolongation of heart allograft survival in rats. Transplantation. 62:1996;986-994.
8. Kahan B.D. The synergistic effects of cyclosporine and sirolimus. Transplantation. 63:1997;170-176. [letter to the Editor].
9. Murgia M.G., Jordan S., Kahan B.D. The side effect profile of sirolimus A phase I study in quiescent cyclosporine-prednisone-treated renal transplant patients . Kidney Int. 49:1996;209-216.
10. Groth CG, the European Sirolimus Renal Transplant Study Group. Early efficacy results from a pilot study of sirolimus versus cyclosporine in association with azathioprine and corticosteroids in the prevention of acute rejection in human renal allograft recipients. 23rd Annual Scientific Meeting of the American Society of Transplant Surgeons 1997; A-223.
11. Kahan B.D., Gibbons S., Tejpal N., Stepkowski S., Chou T.C. Synergistic interaction of cyclosporine and rapamycin to inhibit immune performances for normal human peripheral blood lymphocytes in vitro. Transplantation. 51:1991;232-239.
12. Hitchings G.H. Biochemical background of trimethoprin-sulphamethoxazole. Med J Aust. 1:1973;5-9.
13. Chou T.C., Talalay P. Quantitative analysis of dose-effect relationships The combined effects of multiple drugs or enzyme inhibitors . Adv Enzyme Regul. 22:1984;27-55.
14. Kahan B. Sirolimus a new agent for clinical renal transplantation . Transplant Proc. 29:1997;48-50.
15. Zimmerman J., Kahan B.D. The pharmacokinetics of sirolimus in stable renal transplant patients after multiple oral dose administration. J Clin Pharmacol. 37:1997;405-415.
16. Kahan B.D., Dunn J., Fitts C., et al. Reduced inter- and intrasubject variability in cyclosporine pharmacokinetics in renal transplant recipients treated with a microemulsion formulation in conjunction with fasting, low fat or high fat meals. Transplantation. 59:1995;505-511.
17. Ballantyne C.M., Podet E.J., Patsch W.P., et al. Effects of cyclosporine therapy on plasma lipoprotein levels. JAMA. 262:1989;53-56.
18. Wang M.-E., Stepkowski S.M., Ferraresso M., Kahan B.D. Evidence that rapamycin rescue therapy delays rejection of major (MHC) plus minor (non-MHC) histoincompatible heart allografts in rats. Transplantation. 54:1992;704-709.
19. Slaton J.W., Kahan B.D. Case report-sirolimus rescue therapy for refractory renal allograft rejection. Transplantation. 61:1996;977-979.
20. Schmid C., Heemann U., Tilney N.L. Factors contributing to the development of chronic rejection in heterotopic rat heart transplantation. Transplantation. 64:(2):1997;222-228.
21. Khanna A., Kapur S., Sharma V., Li B., Suthanthiran M. In vivo hyperexpression of transforming growth factor-beta1 in mice stimulation by cyclosporine . Transplantation. 63:(7):1997;1037-1039.
22. Napoli K.L., Kahan B.D. Routine clinical monitoring of sirolimus (rapamycin) whole-blood concentrations by HPLC with ultraviolet detection. Clin Chem. 42:1996;1944-1948.